Health Innovation
3 German Health Startups Built by Repeat Founders
DealBio tracks early-stage health startups across Europe and North America. These 3 German startups are being built by founders who have already created or led earlier ventures and are applying that experience to a new health product.
- Germany
- Repeat Founders
- AI Health
- Neurotech
- Digital Health
Repeat-founder experience is most useful when it changes execution. A founder who has already hired teams, shipped products, raised capital or navigated healthcare partnerships can bring practical pattern recognition into the next venture.
Across Orbion, Nuuron and DocToRead, prior operating experience is showing up in product scope, distribution choices and execution. The common signal is not simply that the founders have built before, but that earlier experience is shaping how each new startup is being taken to market.
At a Glance
01
Orbion
Using AI to predict protein expression, stability and developability before lab work.
- Country
Germany- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
- Founders
Why Orbion stands out
Orbion is applying AI to a specific experimental decision: which protein constructs are most likely to express well and remain stable before a team spends time making them in the lab. QAI Ventures invested in the startup in January 2026.
Co-founder Çağlar Bozkurt brings repeat-founder and product experience from Twentify, which reached more than 100 enterprise customers, as well as later product roles at Taxfix and AMBOSS. That operating background complements Aniruddh Goteti's production machine-learning experience.
What Orbion is building
Orbion's subscription software scores protein sequences for expression, stability and developability, the set of properties that influence whether a candidate can be produced and handled reliably. Teams can compare constructs or mutations before committing to experimental production.
The product is aimed at biotech, pharmaceutical and research teams working on difficult proteins. Its value proposition is fewer failed experimental iterations and a shorter path to a usable protein sample.
02
Nuuron
Developing light-based brain stimulation to treat memory loss in Alzheimer’s disease.
- Country
- Germany
- Founded
- 2023
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why Nuuron stands out
Nuuron raised a €3.5 million seed round backed by High-Tech Gründerfonds and IBB Ventures and has already generated human mechanistic data. In an eight-patient study, the startup observed stronger memory-related brain signals after its visual-stimulation protocol.
The founding team also brings prior health-venture experience. Fabian Queisner previously built digital-health ventures, while Markus Müschenich founded Flying Health and has worked across healthcare innovation and hospital leadership. That background is relevant to a home-use neurotechnology that eventually has to fit clinical care.
What Nuuron is building
Nuuron's Memory Pacemaker uses precisely timed visual stimulation delivered through smart glasses to influence brain activity involved in memory formation and recall. Neurostimulation means using a controlled external stimulus to change nervous-system activity.
The system is designed for non-invasive home use in people with mild cognitive impairment and Alzheimer's disease. Nuuron is pairing the device with software so treatment can be delivered repeatedly rather than only during clinic visits.
Turning medical reports into plain-language explanations for patients.
- Country
- Germany
- Founded
- 2024
- Sector
- Digital health
- Funding stage
- Seed or earlier
- Founders
Why DocToRead stands out
DocToRead has already moved into real use: its patient app has been used thousands of times, and it operates a browser portal for clinics and practices. That gives the product two distribution paths around the same problem, one patient-facing and one integrated into clinical communication.
Founder Bastian Hollmann brings more than two decades of medical-technology and radiology experience and previously founded Hollmann Medical. His earlier work gives DocToRead direct familiarity with how medical information is produced and explained in clinical settings.
What DocToRead is building
Patients photograph or upload medical reports and receive a plain-language explanation that can be read aloud, saved or shared. Optical character recognition, software that converts text in an image into machine-readable text, captures the document before AI simplifies the language.
The clinician portal can generate concise, multilingual or child-friendly versions from the same source material. The aim is to reduce the gap between a technically correct report and a patient's ability to understand what it says.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
The strongest signal in this group is not the repeat-founder label on its own. It is the way prior experience shapes the operating model. Orbion is tightly scoped around a measurable research decision, Nuuron is designed for repeated home use while staying connected to clinical care, and DocToRead addresses a communication workflow its founder already knew from medtech and radiology.
For investors, that makes founder history more informative when it can be traced into product design, distribution or company-building speed. Relevant prior experience does not replace product evidence, but it can make early execution more deliberate.
Methodology
DealBio selected these startups from its coverage of early-stage health and longevity startups, focusing on German businesses where at least one founder has substantial prior venture-building or operating experience that is directly relevant to the new startup.
DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.